Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M14-658: Upadacitinib in Pediatric Ulcerative Colitis
jRCT2011230031Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in autoimmune colitis (5 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving Adapted Mayo Score (AMS) Clinical Remission at Week 8 (Period 1) and Percentage of Participants Achieving AMS Clinical Remission Among Week 8 Responders per AMS at Week 52 (Period 1). Started Dec 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2011230031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230031.